10-Q: SBC Medical Group Q2 Profit Plunges 87%

SBC Medical Group Holdings Incorporated reported a significant decline in net income and negative operating cash flow for Q2 2025, despite growth in procurement and rental services revenue.

Summary

• Net revenues for the three months ended June 30, 2025, decreased by 18.35% to $43.36 million from $53.10 million in the prior year period.
• Net income attributable to SBC Medical Group Holdings Incorporated for Q2 2025 plummeted by 86.70% to $2.46 million, down from $18.48 million in Q2 2024.
• For the six months ended June 30, 2025, net revenues decreased by 15.96% to $90.69 million from $107.91 million in the same period last year.
• Net income attributable to SBC Medical Group Holdings Incorporated for the six months ended June 30, 2025, fell by 35.66% to $23.96 million from $37.24 million in the prior year period.
• Operating expenses for Q2 2025 increased by 27.43% to $15.46 million, primarily due to a significant rise in office, utility, and other expenses, and consulting and professional service fees.
• Cash and cash equivalents increased to $152.74 million as of June 30, 2025, from $125.04 million at December 31, 2024.
• Net cash flow from operating activities for the six months ended June 30, 2025, was negative $6.41 million, a substantial decline from positive $22.87 million in the same period of 2024.
• The company completed its $5 million share repurchase program on July 22, 2025, repurchasing 1,034,308 shares.
• Acquired 100% equity interest in MB Career Lounge Co., Ltd. on July 17, 2025, for approximately $13.7 million.

Sentiment

Score: 3

Explanation: The significant decline in net income and revenues, coupled with negative operating cash flow and un-remediated material weaknesses in internal controls, indicates a poor financial performance despite some growth in specific revenue streams and an increase in cash reserves. The high effective tax rate also negatively impacts profitability.

Positives

• Cash and cash equivalents increased to $152.74 million as of June 30, 2025, from $125.04 million at December 31, 2024.
• Procurement revenue increased by 16.40% for Q2 2025 and 12.56% for H1 2025, driven by orders for new medical materials.
• Rental services revenue surged by 98.40% for Q2 2025 and 76.66% for H1 2025, attributed to new clinic openings and equipment replacement.
• Realized a significant gain on redemption of life insurance policies of $8.75 million for the six months ended June 30, 2025.
• Recognized a gain of $111,632 from the change in fair value of cryptocurrencies for the six months ended June 30, 2025.

Negatives

• Net income attributable to SBC Medical Group Holdings Incorporated decreased by 86.70% for Q2 2025 and 35.66% for H1 2025.
• Total revenues, net, decreased by 18.35% for Q2 2025 and 15.96% for H1 2025.
• Franchising revenue declined by 31.58% for Q2 2025 and 13.48% for H1 2025 due to a revision in the fee structure.
• Management services revenue decreased significantly by 69.24% for Q2 2025 and 57.15% for H1 2025, primarily due to the discontinuation of clinic operation staff supporting services and changes in the customer rewards program.
• Gross profit decreased by 23.87% for Q2 2025 and 14.18% for H1 2025, mainly due to the decline in high-margin franchising and management services revenue.
• Operating expenses increased by 27.43% for Q2 2025 and 6.62% for H1 2025, driven by a substantial increase in office, utility, and other expenses (28,315.53% for Q2) and consulting and professional service fees (50.42% for Q2).
• Net cash used in operating activities was $6.41 million for the six months ended June 30, 2025, a significant negative shift from $22.87 million provided in the prior year period.
• The effective tax rate increased to 81.98% for Q2 2025 and 46.81% for H1 2025, primarily due to a deemed taxable gain from the price modification on the disposal of an aircraft to a related party.

Risks

• Exposure to foreign currency exchange rate fluctuations, particularly the Japanese Yen against the U.S. dollar, as most revenues and costs are denominated in JPY.
• Material weaknesses in disclosure controls and procedures remained un-remediated as of June 30, 2025, indicating a risk to the reliability of financial reporting.
• Reliance on related parties for a significant portion of revenues and accounts receivable, with customer A, B, and C representing 25%, 25%, and 22% of total revenues for H1 2025, and 27%, 25%, and 24% of total outstanding accounts receivable as of June 30, 2025.
• The company's ability to forecast and maintain an adequate rate of revenue growth and appropriately plan its expenses.
• Intense competition and competitive pressures from other companies in the industries in which the company operates.
• The possibility that the company may be adversely affected by other economic, business, and/or competitive factors.

Future Outlook

The company plans to maintain and strengthen its market position and brand in the cosmetic medical treatment management market in Japan, Vietnam, and Singapore, and grow its presence globally. It expects to deploy capital for investment opportunities aligned with its growth strategy in the expanding global medical aesthetics market. The company believes its current cash and cash equivalents from operations and bank borrowings will be sufficient for working capital needs for the next 12 months. The impact of the One Big Beautiful Bill Act (OBBBA) on consolidated financial statements is currently being assessed, with effects to be recognized starting in the period it was signed into law.

Management Comments

• Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures and concluded they were not effective as of June 30, 2025, due to identified material weaknesses.
• We remain committed to ongoing improvements in our disclosure controls and internal control over financial reporting, including execution of the remediation plan disclosed in our Annual Report on Form 10-K.
• We believe that our unaudited consolidated financial statements and other information contained in this Quarterly Report fairly present, in all material respects, our financial condition, and results of operations for the periods presented, despite the identified material weaknesses.

Industry Context

The company operates in the medical industry, providing comprehensive management services to medical corporations and their clinics, primarily in Japan, with a growing presence in Vietnam and Singapore. The company aims to expand its Shonan Beauty Clinic brand globally, indicating a focus on the expanding global medical aesthetics market. The decline in franchising and management services revenue, coupled with growth in procurement and rental services, suggests a shift in revenue mix or challenges in core service areas, potentially reflecting competitive pressures or market saturation in certain segments, while new clinic openings and equipment demand drive other segments.

Comparison to Industry Standards

• NA The filing does not provide specific comparable companies, projects, or results to assess against global benchmarks.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any material litigation or other legal proceedings.

Related Party Transactions

• Revenues from related parties (Medical Corporations Shobikai, Kowakai, Nasukai, Aikeikai, Jukeikai, Ritz Cosmetic Surgery, Association Furinkai, Association Junikai, Japan Medical & Beauty Inc., Hariver Inc., SBC Inc., Public Interest Foundation SBC Medical Promotion Foundation, SBC Tokyo Medical University, SBC Shonan Osteopathic Clinic Inc., Yoshiyuki Aikawa, AI Med Inc., SBC Irvine MC, General Incorporated Association Taiseikai, Skynet Academy Co., Ltd., Kijimadairakanko Inc.) totaled $84.20 million for the six months ended June 30, 2025.
• Cost of revenues from related parties totaled $8.13 million for the six months ended June 30, 2025.
• Selling, general and administrative expenses from related parties totaled $415,767 for the six months ended June 30, 2025.
• Accounts receivable from related parties totaled $48.92 million as of June 30, 2025.
• Finance lease receivables from related parties totaled $22.33 million as of June 30, 2025.
• Other receivables from related parties totaled $1.89 million as of June 30, 2025.
• Long-term investments in Medical Corporations (MCs) totaled $19.38 million as of June 30, 2025.
• Accounts payable to related parties totaled $3.25 million as of June 30, 2025.
• Advances from customers (related parties) totaled $10.33 million as of June 30, 2025.
• Notes and other payables to related parties totaled $3.27 million as of June 30, 2025.
• Due to related party (Yoshiyuki Aikawa) totaled $2.81 million as of June 30, 2025.
• A subsidiary provided a guarantee on the debt of its CEO in the amount of $266,573 as of June 30, 2025.
• In June 2025, the company entered into a memorandum of sale for an aircraft with General Incorporated Association SBC (controlled by the CEO), with the original sale price increased by approximately $9.68 million, recorded as a deemed contribution.

Stakeholder Impact

• Shareholders: Significant decline in net income and negative operating cash flow may raise concerns about profitability and future returns. The share repurchase program could provide some support, but the CEO's 10b5-1 plan for selling shares might be viewed negatively.
• Employees: Discontinuation of clinic operation staff supporting services and related staff termination may impact employment stability in certain areas.
• Customers (MCs and End Customers): Revision of fee structures for franchising and management services may impact MCs. The company continues to provide loan services to End Customers.
• Creditors: The shift to negative operating cash flow and reliance on bank borrowings for working capital may warrant closer monitoring, though overall cash position remains strong.
• Regulatory Authorities: Un-remediated material weaknesses in disclosure controls and procedures could lead to increased scrutiny.

Next Steps

• Assess the impact of the One Big Beautiful Bill Act (OBBBA) on consolidated financial statements, with effects to be recognized starting in the period it was signed into law (July 4, 2025).
• Continue efforts to improve disclosure controls and internal control over financial reporting, including execution of the remediation plan.
• Deploy capital for investment opportunities that align with the growth strategy in the global medical aesthetics market.
• CEO Yoshiyuki Aikawa's Rule 10b5-1 trading arrangement for potential sale of up to 1,030,000 shares is set to begin sales from September 22, 2025.

Key Dates

Recommendation

The company faces significant headwinds with substantial declines in net income and overall revenues, coupled with a shift to negative operating cash flow. Un-remediated material weaknesses in internal controls also present a concern. While there are positive signs in procurement and rental services revenue growth, and a strong cash position, the core business segments are under pressure due to fee structure revisions and service discontinuations. The recent acquisition and share repurchase program indicate active capital management, but the overall financial performance suggests a period of adjustment and uncertainty. A 'hold' recommendation is appropriate as investors should monitor the effectiveness of remediation efforts for internal controls, the impact of new fee structures, and the company's ability to return to positive operating cash flow and sustained profitability before considering further investment.

Keywords

Medical Group, Cosmetic Treatment, Healthcare Management, Japan, Singapore, Vietnam, SEC Filing, 10-Q, Financial Results, Revenue, Net Income, Operating Cash Flow, Share Repurchase, Internal Controls, Related Party Transactions, Franchising, Procurement, Management Services, Rental Services